Expression of claudins and their prognostic significance in noninvasive urothelial neoplasms of the human urinary bladder

Journal of Histochemistry and Cytochemistry

Volumn 59, Issue 10, 2011, Pages 932-941

  Székely, Eszter ^a   Törzsök, Péter ^a   Riesz, Péter ^b   Korompay, Anna ^a   Fintha, Attila ^a   Székely, Tamás ^a   Lotz, Gábor ^a   Nyirády, Péter ^b   Romics, Imre ^b   Tímár, József ^a   Schaff, Zsuzsa ^a   Kiss, András ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

claudin; inverted urothelial papilloma; low grade; PUNLMP; urothelial cell cancer; urothelial papilloma

Indexed keywords

CLAUDIN 1; CLAUDIN 2; CLAUDIN 4; CLAUDIN 7;

ARTICLE; CANCER CELL; CANCER GRADING; CONTROLLED STUDY; DATA ANALYSIS; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVERTED PAPILLOMA; MALE; PAPILLOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; UROGENITAL TRACT CANCER; UROGENITAL TRACT TUMOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; CHILD; CLAUDINS; FEMALE; GENE EXPRESSION; HUMANS; MALE; MIDDLE AGED; PAPILLOMA; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 80054842830     PISSN: 00221554     EISSN: None     Source Type: Journal    
DOI: 10.1369/0022155411418829     Document Type: Article

References (36)

1. Awsare N,Martin T,Haynes M,Watkins G,Matthews P,Jiang W.The expression of tight junction proteins claudins 11 and 15 in normal human urothelium and transitional cell carcinoma.BJU Int. 2007;99:46-47.
2. Boireau S,Buchert M,Samuel MS,Pannequin J,Ryan JL,Choquet A,Chapuis H,Rebillard X,Avances C,Ernst M, et al.DNA-methylation-dependent alterations of claudin-4 expression in human bladder carcinoma.Carcinogenesis. 2007;28:246-258.
3. Bryan RT,Zeegers MP,James ND,Wallace DM,Cheng KK.Biomarkers in bladder cancer.BJU Int. 2010;105:608-613.
4. Castillo-Martin M,Domingo-Domenech J,Karni-Schmidt O,Matos T,Cordon-Cardo C.Molecular pathways of urothelial development and bladder tumorigenesis.Urol Oncol. 2010;28:401-408.
5. Cheville JC,Wu K,Sebo TJ,Cheng L,Riehle D,Lohse CM,Shane V.Inverted urothelial papilloma: is ploidy, MIB-1 proliferative activity, or p53 protein accumulation predictive of urothelial carcinoma?.Cancer. 2000;88:632-636.
6. Eiber M,van Oers JM,Zwarthoff EC,van der Kwast TH,Ulrich O,Helpap B,Stoerkel S,Blaszyk H,Cheville J,Sauter G, et al.Low frequency of molecular changes and tumor recurrence in inverted papillomas of the urinary tract.Am J Surg Pathol. 2007;31:938-946.
7. Forster C.Tight junctions and the modulation of barrier function in disease.Histochem Cell Biol. 2008;130:55-70.
8. Huo Q,Kinugasa T,Wang L,Huang J,Zhao J,Shibaguchi H,Kuroki M,Tanaka T,Yamashita Y,Nabeshima K,Iwasaki H.Claudin-1 protein is a major factor involved in the tumorigenesis of colorectal cancer.Anticancer Res. 2009;29:851-857.
9. Jones TD,Wang M,Eble JN,MacLennan GT,Lopez-Beltran A,Zhang S,Cocco A,Cheng L.Molecular evidence supporting field effect in urothelial carcinogenesis.Clin Cancer Res. 2005;11:6512-6519.
10. Jones TD,Zhang S,Lopez-Beltran A,Eble JN,Sung MT,MacLennan GT,Montironi R,Tan PH,Zheng S,Baldridge LA,Cheng L.Urothelial carcinoma with an inverted growth pattern can be distinguished from inverted papilloma by fluorescence in situ hybridization, immunohistochemistry, and morphologic analysis.Am J Surg Pathol. 2007;31:1861-1867.
11. Kaufmann O,Fietze E,Mengs J,Dietel M.Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas.Am J Clin Pathol. 2001;116:823-830.
12. Kinugasa T,Huo Q,Higashi D,Shibaguchi H,Kuroki M,Tanaka T,Futami K,Yamashita Y,Hachimine K,Maekawa S, et al.Selective up-regulation of claudin-1 and claudin-2 in colorectal cancer.Anticancer Res. 2007;27:3729-3734.
13. Krajewska M,Olson AH,Mercola D,Reed JC,Krajewski S.Claudin-1 immunohistochemistry for distinguishing malignant from benign epithelial lesions of prostate.Prostate. 2007;67:907-910.
14. Lechpammer M,Resnick MB,Sabo E,Yakirevich E,Greaves WO,Sciandra KT,Tavares R,Noble LC,DeLellis RA,Wang LJ.The diagnostic and prognostic utility of claudin expression in renal cell neoplasms.Mod Pathol. 2008;21:1320-1329.
15. Lodi C,Szabo E,Holczbauer A,Batmunkh E,Szijarto A,Kupcsulik P,Kovalszky I,Paku S,Illyes G,Kiss A,Schaff Z.Claudin-4 differentiates biliary tract cancers from hepatocellular carcinomas.Mod Pathol. 2006;19:460-469.
16. Lott S,Wang M,Zhang S,MacLennan GT,Lopez-Beltran A,Montironi R,Sung MT,Tan PH,Cheng L.FGFR3 and TP53 mutation analysis in inverted urothelial papilloma: incidence and etiological considerations.Mod Pathol. 2009;22:627-632.
17. Martin TA,Jiang WG.Loss of tight junction barrier function and its role in cancer metastasis.Biochim Biophys Acta. 2009;1788:872-891.
18. Mees ST,Mennigen R,Spieker T,Rijcken E,Senninger N,Haier J,Bruewer M.Expression of tight and adherens junction proteins in ulcerative colitis associated colorectal carcinoma: upregulation of claudin-1, claudin-3, claudin-4, and beta-catenin.Int J Colorectal Dis. 2009;24:361-368.
19. Montironi R,Mazzucchelli R,Scarpelli M,Lopez-Beltran A,Cheng L.Morphological diagnosis of urothelial neoplasms.J Clin Pathol. 2008;61:3-10.
20. Nakanishi K,Ogata S,Hiroi S,Tominaga S,Aida S,Kawai T.Expression of occludin and claudins 1, 3, 4, and 7 in urothelial carcinoma of the upper urinary tract.Am J Clin Pathol. 2008;130:43-49.
21. Nemeth Z,Szasz AM,Tatrai P,Nemeth J,Gyorffy H,Somoracz A,Szijarto A,Kupcsulik P,Kiss A,Schaff Z.Claudin-1, -2, -3, -4, -7, -8, and -10 protein expression in biliary tract cancers.J Histochem Cytochem. 2009;57:113-121.
22. Ouban A,Ahmed AA.Claudins in human cancer: a review.Histol Histopathol. 2010;25:83-90.
23. Paschoud S,Bongiovanni M,Pache JC,Citi S.Claudin-1 and claudin-5 expression patterns differentiate lung squamous cell carcinomas from adenocarcinomas.Mod Pathol. 2007;20:947-954.
24. Resnick MB,Konkin T,Routhier J,Sabo E,Pricolo VE.Claudin-1 is a strong prognostic indicator in stage II colonic cancer: a tissue microarray study.Mod Pathol. 2005;18:511-518.
25. Riesz P,Szekely E,Torzsok P,Majoros A,Szendroi A,Dombovari P,Romics I.[Can inverted papilloma in urinary bladder be considered as a benign tumor].Orv Hetil. 2010;151:92-95.
26. Saeki R,Kondoh M,Kakutani H,Matsuhisa K,Takahashi A,Suzuki H,Kakamu Y,Watari A,Yagi K.A claudin-targeting molecule as an inhibitor of tumor metastasis.J Pharmacol Exp Ther. 2010;334:576-582.
27. Saeki R,Kondoh M,Kakutani H,Tsunoda S,Mochizuki Y,Hamakubo T,Tsutsumi Y,Horiguchi Y,Yagi K.A novel tumor-targeted therapy using a claudin-4-targeting molecule. Mol Pharmacol. 2009;76:918-926.
28. Samaratunga H,Makarov DV,Epstein JI.Comparison of WHO/ISUP and WHO classification of noninvasive papillary urothelial neoplasms for risk of progression.Urology. 2002;60:315-319.
29. Sheehan GM,Kallakury BV,Sheehan CE,Fisher HA,Kaufman RP,Ross JS.Loss of claudins-1 and -7 and expression of claudins-3 and -4 correlate with prognostic variables in prostatic adenocarcinomas.Hum Pathol. 2007;38:564-569.
30. Sobel G,Nemeth J,Kiss A,Lotz G,Szabo I,Udvarhelyi N,Schaff Z,Paska C.Claudin 1 differentiates endometrioid and serous papillary endometrial adenocarcinoma.Gynecol Oncol. 2006;103:591-598.
31. Stravoravdi P,Natsis K,Kirtsis P,Retalis G,Konstandinidis E,Polyzonis M.Ultrastructural study of the noninvolved urothelium of tumor-bearing patients after two years of intravesical interferon therapy.Eur Urol. 1996;29:477-482.
32. Sung MT,Eble JN,Wang M,Tan PH,Lopez-Beltran A,Cheng L.Inverted papilloma of the urinary bladder: a molecular genetic appraisal.Mod Pathol. 2006a;19:1289-1294.
33. Sung MT,Maclennan GT,Lopez-Beltran A,Montironi R,Cheng L.Natural history of urothelial inverted papilloma.Cancer. 2006b;107:2622-2627.
34. Tokes AM,Kulka J,Paku S,Szik A,Paska C,Novak PK,Szilak L,Kiss A,Bogi K,Schaff Z.Claudin-1, -3 and -4 proteins and mRNA expression in benign and malignant breast lesions: a research study.Breast Cancer Res. 2005;7:R296-R305.
35. van Oers JM,Wild PJ,Burger M,Denzinger S,Stoehr R,Rosskopf E,Hofstaedter F,Steyerberg EW,Klinkhammer-Schalke M,Zwarthoff EC, et al.FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours.Eur Urol. 2007;52:760-768.
36. Varley CL,Garthwaite MA,Cross W,Hinley J,Trejdosiewicz LK,Southgate J.PPARgamma-regulated tight junction development during human urothelial cytodifferentiation.J Cell Physiol. 2006;208:407-417.